ライフサイエンスコーパス: squamous cell cancer

1 ng cART in an HIV-1-infected patient who had squamous cell cancer.

2 iene receptors was deregulated in esophageal squamous cell cancer.

3 squamous dysplasia and inflammation-mediated squamous cell cancer.

4 melanoma cancer, either basal cell cancer or squamous cell cancer.

5 t are frequently altered in human esophageal squamous cell cancer.

6 marker in breast carcinoma and oropharyngeal squamous cell cancer.

7 multiple genes that are mutated in cutaneous squamous cell cancers.

8 treatment of locally advanced head and neck squamous cell cancers.

9 nce the effect of chemotherapy on esophageal squamous cell cancers.

10 racterized by an increased susceptibility to squamous cell cancers.

11 d with arterial aneurysms, autoimmunity, and squamous cell cancers.

12 mutations found in the p53 gene of basal and squamous cell cancers.

13 ression was lost concurrently with NOTCH1 in squamous cell cancers.

14 eChips were used to profile 59 head and neck squamous cell cancers.

15 n, a hallmark feature of well-differentiated squamous cell cancers.

16 orly differentiated cancer specimens than in squamous cell cancers.

17 inoid with preclinical antitumor activity in squamous cell cancers.

18 %) ciclosporin users developed a total of 20 squamous cell cancers.

19 ge: 60.1 years; adenocarcinoma: 25 patients; squamous cell cancer: 21 patients).

20 fifteen patients had adenocarcinoma, 16 had squamous cell cancer, 6 had another form of esophageal t

21 ssion also decreased, especially in invasive squamous cell cancer (70% loss).

22 Patients characteristics were as follows: squamous cell cancer, 90% versus 85%; weight loss greate

23 Squamous cell cancers account for more than half of all

24 Esophageal squamous cell cancer accounts for more than 90% of cases

25 quency of 0.7 (prostate cancer) to 9.9 (lung squamous cell cancer), all tumor types from white patien

26 iopsy samples of 19 patients with esophageal squamous cell cancer and 9 sex- and age-matched patients

27 rmine the molecular mechanisms of esophageal squamous cell cancer and inflammation-mediated carcinoge

28 nd invasive epithelium from human esophageal squamous cell cancer and prostatic adenocarcinoma.

29 e CRT in patients with localised oesophageal squamous-cell cancer and adenocarcinomas to assess activ

30 Human squamous cell cancers are the most common epithelially d

31 n found to be efficacious for basal cell and squamous cell cancers, as well as cutaneous T-cell lymph

32 ving outcomes of patients with head and neck squamous cell cancer, both human papilloma virus-associa

33 esistant colorectal cancer and head and neck squamous cell cancer cell lines and in tumors from color

34 al analyses, showed that human head and neck squamous cell cancer cells express heretofore unrecogniz

35 s were significantly increased in esophageal squamous cell cancer compared to control mucosa (p < 0.0

36 Squamous cell cancers comprise the most common type of h

37 Conversely, squamous cell cancer comprised 60% of the rapid DT group

38 cently demonstrated that human head and neck squamous cell cancers contain a tumorigenic, so-called c

39 Among human malignancies, head and neck squamous cell cancer displays a marked predilection for

40 Among patients with early-stage oral squamous-cell cancer, elective neck dissection resulted

41 onal PIK3R1 and mTOR SNPs in 1116 esophageal squamous cell cancer (ESCC) patients and 1117 cancer-fre

42 ents with esophageal adenocarcinoma (EAC) or squamous cell cancer (ESCC) present with advanced, incur

43 10 was compared with uptake in head and neck squamous cell cancer FaDu (intermediate EpCAM) and promy

44 treatment of locally advanced head and neck squamous cell cancer has advanced greatly in recent year

45 se in incidence of a subset of head and neck squamous cell cancers (HNCs) in numerous geographic regi

46 es for patients with high-risk head and neck squamous cell cancer (HNSCC) after surgical resection by

47 The treatment paradigms for head and neck squamous cell cancer (HNSCC) are changing due to the eme

48 ternalization of HN-1 by human head and neck squamous cell cancer (HNSCC) cells suggests that HN-1 is

49 GFR1-dependent lung cancer and head and neck squamous cell cancer (HNSCC) cells to ponatinib, a multi

50 ll cell lung cancer (NSCLC) or head and neck squamous cell cancer (HNSCC) compared with inflammatory

51 umor-free" surgical margins of head and neck squamous cell cancer (HNSCC) patients is an independent

52 ival in patients with advanced head and neck squamous cell cancer (HNSCC) remains dismal.

53 Appropriate treatment of head and neck squamous cell cancer (HNSCC) remains one of the most dif

54 the follow-up of patients with head and neck squamous cell cancer (HNSCC).

55 th the etiology of a subset of head and neck squamous cell cancer (HNSCC).

56 prognostic value for resected head and neck squamous cell cancer (HNSCC).

57 Head and neck squamous cell cancers (HNSCC) have a high local recurren

58 ctor, is found elevated in all head and neck squamous cell cancers (HNSCC).

59 del of human papillomavirus (HPV)-associated squamous cell cancers, HPV16 E6 and E7 oncogenes and E1

60 )-2 has been demonstrated to protect against squamous cell cancer in many studies.

61 insights into the molecular pathogenesis of squamous cell cancers in general.

62 acilitate the formation of HPV E6/E7-induced squamous cell cancers in mice using a transposon-mediate

63 pregulating TAp63 and preventing or treating squamous cell cancers in the general non-FA population.

64 How monoubiquitinated FANCD2 suppresses squamous cell cancers is unknown.

65 most frequent of the HPV types detected when squamous-cell cancer is diagnosed and the type most stro

66 NUT midline carcinoma (NMC), a subtype of squamous cell cancer, is one of the most aggressive huma

67 rd of care in locally advanced head and neck squamous cell cancer (LAHNSCC).

68 of skin cancers including basal cell cancer, squamous cell cancer, lentigo maligna melanoma and cutan

69 In contrast, the squamous cell cancer-like (SCCL) subtype uniformly expre

70 ment for Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Cancer (LSCC) and the ERK2-VTX11e treatmen

71 olon cancer, breast cancer, prostate cancer, squamous cell cancer, lymphoma, and leiomyosarcoma, sugg

72 ng dose-limiting toxicity in a head and neck squamous cell cancer murine model.

73 (ATZ), 1 (0.03%) with pouch lymphoma, 3 with squamous cell cancer of the ATZ, and 23 with dysplasia (

74 in patients with prior chemotherapy-treated squamous cell cancer of the cervix.

75 mitant chemoradiotherapy in locally advanced squamous cell cancer of the head and neck (LASCCHN).

76 f docetaxel, cisplatin, and fluorouracil for squamous cell cancer of the head and neck (SCCHN) and to

77 irradiation or chemotherapy agents active in squamous cell cancer of the head and neck could increase

78 The overall survival of patients with squamous cell cancer of the head and neck has not signif

79 nd 5-fluorouracil in patients with recurrent squamous cell cancer of the head and neck.

80 The risk of squamous cell cancer of the skin is increased by ciclosp

81 nt radiation in patients with poor-prognosis squamous cell cancers of the anal canal.

82 s a major risk factor for the development of squamous cell cancers of the cervix and of the head and

83 eIF4E in the tumors and surgical margins of squamous cell cancers of the larynx and to determine the

84 med on 54 patients who underwent surgery for squamous cell cancers of the larynx.

85 were strongly linked with an excess risk of squamous-cell cancers of the buccal cavity and skin.

86 ly when applied to HPV-related oropharyngeal squamous cell cancer (OPSCC), leading to calls for a new

87 havior of a number of cancers including oral squamous cell cancer (OSCC), and increased expression of

88 Among squamous cell cancers, p53 mutations were detected signi

89 e novel approaches to treating head and neck squamous cell cancer, particularly the introduction of b

90 sponse and survival outcome in head and neck squamous cell cancer patients (HNSCC).

91 inses from a separate group of head and neck squamous cell cancer patients contained detectable telom

92 nstructs that mimicked the initial stages of squamous cell cancer progression.

93 part in suppressing the incipient stages of squamous cell cancer progression.

94 mutations occur in approximately 4% of lung squamous cell cancer (SCC) where the tyrosine kinase inh

95 Although it is known that squamous cell cancers (SCC) are caused by UV light, the

96 X expression has been reported in esophageal squamous cell cancers (SCC).

97 atients with FA have a high baseline risk of squamous cell cancers (SCCs) of the head, neck, and esop

98 ed by its pathogenic mutations in esophageal squamous cell cancers (SCCs).

99 ia in human head and neck and uterine cervix squamous cell cancers (SCCs).

100 A rise in incidence of oropharyngeal squamous cell cancer--specifically of the lingual and pa

101 26 of 35 (80%) primary, fresh, head and neck squamous cell cancer specimens and 3 of 6 head and neck

102 Esophageal cancer is a prototypic squamous cell cancer that carries a poor prognosis, prim

103 L2-cre;p120ctnLoxP/LoxP mice, which develop squamous cell cancers that resemble human ESCC, we visua

104 lls as a platform to recapitulate esophageal squamous cell cancer, thereby providing insights into th

105 otherapeutic agent usedagainst head and neck squamous cell cancer to date.

106 To examine E-cadherin loss in squamous cell cancers, we used primary human esophageal

107 with stage III or IV glottic or supraglottic squamous cell cancer were randomly assigned to induction

108 vival outcomes in lung cancer, especially in squamous cell cancers where p53 abnormalities are more c

109 in BCC patients treated with Smo inhibitor, squamous cell cancers with RAS/MAPK activation emerged f

110 In cisplatin-resistant human squamous cell cancer xenografts in nude mice, this combi